SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

  • Post author:
  • Post category:News

SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® Positive results show Pentarlandir is safe and effective in patients with mild-to-moderate COVID-19 Press Release...

Continue ReadingSyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

Dr. Joseph T. Coyle Named Chair of SyneuRx’s Scientific Advisory Board

  • Post author:
  • Post category:News

Dr. Joseph T. Coyle Named Chair of SyneuRx’s Scientific Advisory Board Renowned neuroscientist known for his groundbreaking discoveries in psychiatric disorders joins advisory board to drive clinical development efforts Press...

Continue ReadingDr. Joseph T. Coyle Named Chair of SyneuRx’s Scientific Advisory Board

SyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

  • Post author:
  • Post category:News

SyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01) Early research suggests Pentarlandir is safe to use against COVID-19; Phase 3 trial evaluating...

Continue ReadingSyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

Q&A with SyneuRx Chief Scientist and CEO., Emil Tsai, M.D.–Ph.D., M.A.S.: What are the top Symptoms of the BA.2 Variant and is it a Major Cause for Concern?

  • Post author:
  • Post category:Blog

Q&A with SyneuRx Chief Scientist and CEO, Dr. Emil Tsai: What Are The Top Symptoms of The BA.2 Variant and Is It a Major Cause of Concern? Since the beginning...

Continue ReadingQ&A with SyneuRx Chief Scientist and CEO., Emil Tsai, M.D.–Ph.D., M.A.S.: What are the top Symptoms of the BA.2 Variant and is it a Major Cause for Concern?

SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants

  • Post author:
  • Post category:News

SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants Acting as Both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir® is...

Continue ReadingSyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants

SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir Has Entered Final Portion of FDA Phase II Testing

  • Post author:
  • Post category:News

SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir® Has Entered Final Portion of FDA Phase II Testing Based on Highly-Purified Isomers of Tannic Acid and Acting as a Dual...

Continue ReadingSyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir Has Entered Final Portion of FDA Phase II Testing

SyneuRx Announces Closing of Public Offering

  • Post author:
  • Post category:News

SyneuRx Announces Closing of Public Offering Press Release Jun 23, 2021 Taipei, Taiwan, June 23, 2021 -- SyneuRx International (Taiwan) Corp. (TWSE:6575) today announced the closing of its public offering...

Continue ReadingSyneuRx Announces Closing of Public Offering

Taiwan FDA Approves SyneuRx’s IND Application for COVID-19 Clinical Trial

  • Post author:
  • Post category:News

Taiwan FDA Approves SyneuRx’s IND Application for COVID-19 Clinical Trial Press Release Jun 08, 2021 Taipei, Taiwan, June 8, 2021 -- SyneuRx International (Taiwan) Corp. (TWSE: 6575), announced today that an IND application for...

Continue ReadingTaiwan FDA Approves SyneuRx’s IND Application for COVID-19 Clinical Trial

SyneuRx Files an IND Application for COVID-19 Clinical Trial in Taiwan

  • Post author:
  • Post category:News

SyneuRx Files an IND Application for COVID-19 Clinical Trial in Taiwan Press Release Jun 03, 2021   Taipei, Taiwan, June 3rd, 2021 -- SyneuRx International (Taiwan) Corp. (TWSE: 6575), announced today that an IND application for SNB011, using its...

Continue ReadingSyneuRx Files an IND Application for COVID-19 Clinical Trial in Taiwan

SyneuRx Initiates Clinical Trial SNB01 Pentarlandir® For Covid-19

  • Post author:
  • Post category:News

SyneuRx Initiates Clinical Trial SNB01 Pentarlandir® For Covid-19 Press Release Apr 27, 2021   Taipei, Taiwan, April 27, 2021 -- SyneuRx International (Taiwan) Corp. (TWSE:6575), announced today that a kick-off meeting...

Continue ReadingSyneuRx Initiates Clinical Trial SNB01 Pentarlandir® For Covid-19